Trial Profile
Randomized phase II study of biweekly gemcitabine-paclitaxel, biweekly gemcitabine-carboplatin and biweekly gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Carboplatin; Cisplatin; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 23 Feb 2010 Actual end date (1 Nov 2009) added as reported by ClinicalTrials.gov record.
- 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Sep 2009 Actual patient number (147) added as reported by ClinicalTrials.gov.